New treatment for MS shows promise
According to new research from Australia, a treatment typically used for Epstein-Barr virus (EBV) may help improve symptoms of multiple sclerosis (MS)—an inflammatory disease that attacks the central nervous system.
Scientists tested the treatment for six weeks on a 43-year-old man with secondary progressive MS. The approach, called adoptive therapy, involved taking blood from the patient, from which more of his T cells grew; the cells were added to the EBV vaccine, then were transferred back into the patient. This is the first time this treatment has been tested on a patient with progressive MS.
The findings, published in Multiple Sclerosis Journal, showed that the patient showed “significant improvement” in the following symptoms: attention, memory, hand function, increased work productivity and a reduction in fatigue and muscle spasms. An MRI also showed that the patient had decreased disease activity in his brain. The patient, named Gary Allen, called the results “an amazing change for the better.”
Researchers said the treatment needs to be tested in a clinical trial to ensure its safety and effectiveness for other people with various types of MS.